Greenhaven Associates 13F: Adds $40M to BDX Stake
Key Points
- Greenhaven Associates now holds 5,904,730 shares of Becton, Dickinson, representing a 3.9% increase in their position.
- The recent share price of Becton, Dickinson is about equal to its event closing price of $196.39 on October 26, 2026.
- Greenhaven's investment in Becton, Dickinson accounts for 37.49% of its overall portfolio, ranking second among its 27 reported positions.
Get Becton, Dickinson and Company text alerts
We text you when insiders, Congress, analysts or big funds move on $BDX.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Becton, Dickinson and Company alert may contain errors. Disclosures
Greenhaven Associates boosted its stake in Becton, Dickinson and Company (NYSE: BDX) by adding 223,022 shares in a filing on October 26, 2026.
BDX
Becton, Dickinson and Company
Where Becton, Dickinson Fits in Greenhaven Associates' Portfolio
Greenhaven's investment in Becton, Dickinson makes up 37.49% of its total reported value, ranking it second among the fund's 27 positions.
Other Institutional Activity in Becton, Dickinson
James Hambro & Partners raised its stake in Becton, Dickinson by 39,543 shares, bringing its total to 335,229 shares worth about $60.0 million. Vanguard Fiduciary Trust also increased its holdings by 1,603,444 shares, now owning 1,603,444 shares valued at approximately $242.6 million. In contrast, Commonwealth Equity Services reduced its position by 37,653 shares, resulting in 78,299 shares worth about $12.2 million.
Becton, Dickinson and Company Stock Down 1.3%
Becton, Dickinson shares traded recently around $196.39, which is about equal to the closing price on October 26, 2026. The stock is currently above its 50-day moving average by 5.8% and its 200-day moving average by 18.8%. However, it remains 2.0% below its 52-week high of $200.47.
Recent Earnings
Becton, Dickinson reported trailing twelve-month revenue of approximately $22.48 billion, with an earnings per share (EPS) of $4.3. The next earnings report is scheduled for November 5, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target raises vs 1 cuts.
-
EPS & revenue
EPS beat estimates by 3.5%. Revenue met estimates.
-
Profit surprise
EBITDA missed by 86 percent. Operating income missed by 91 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
2 target raises, 1 target cut.
-
Earnings quality
Gross margin up 2.9 points. Operating margin down 8.4 points. Positive free cash flow.
Earnings Call Summary
BDX closed its Waters separation today and reported stronger-than-expected first-quarter results with $5.3 billion in revenue and $2.91 in earnings per share. Growth areas like PureWick and biologic drug delivery are performing well with double-digit gains, though China vaccines and Alaris remain headwinds. Management is investing aggressively in high-growth categories and has already captured 80 GLP-1 molecules in drug delivery devices.
Guidance BDX expects about $12.50 in adjusted earnings per share for the full year, roughly 6 percent growth after tariffs. Management said low single-digit revenue growth is on track. They plan to return $4 billion from the Waters separation through buybacks and debt paydown.
Neutral report. Results and guidance were close to expectations, with limited evidence of a reset either way.
Dividend
Becton, Dickinson pays an annual dividend of $4.20 per share, which yields about 2.14%. The dividend payout ratio stands at 72.5%.
Insider Buying and Selling at Becton, Dickinson and Company
Several insiders sold shares recently, including Chief Executive Officer Thomas E. Polen Jr., who sold 4,152 shares at $185.00 each on August 13, 2026, totaling approximately $768,120. Officer Roland Goette sold 2,438 shares at an average price of $180.84 on August 11, 2026, for about $440,888.
Analysts Set New Price Targets
On August 7, 2026, Citigroup maintained its 'Buy' rating on Becton, Dickinson with a price target of $204. RBC Capital also maintained a 'Sector Perform' rating with a target of $190. The consensus recommendation for Becton, Dickinson is 'Buy', with a mean price target of $195.57 from 14 analyst opinions.
About Becton, Dickinson and Company
Becton, Dickinson and Company develops and sells medical supplies and devices, laboratory equipment, and diagnostic products across the globe. The company serves healthcare institutions, researchers, and the pharmaceutical industry, making it a key player in the healthcare sector.
Bottom Line
Investors should watch for Becton, Dickinson's upcoming earnings report on November 5, 2026, and any further filings from Greenhaven Associates. The fund's recent increase in its stake reflects a strong belief in the company's ongoing growth potential.
Related Filing Alerts
Source: Greenhaven Associates's 13F filing on $BDX (Oct 26, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts